Abstract 12P
Background
Context: The AXL receptor tyrosine kinase plays a key role in enabling the immune system and developing resistance to treatment, resulting in a more aggressive tumour. AXL is a receptor tyrosine kinase that is involved in the promotion of epithelial-to-mesenchymal transition and is inhibited by bemcentinib. It also acts as a mechanism of resistance to PD1 or PDL1 targeted immune checkpoint blockade (ICB). Objective: This study aimed to interrogate molecular and cellular mechanisms underlying the response to dual bemcentinib and pembrolizumab (Bem/Pem) treatment in patients with relapsed mesothelioma enrolled in a phase II multicentre clinical trial (MIST3, NCT03654833).
Methods
Archival formalin fixed paraffin embedded tissues and blood samples were collected from the MIST3 cohort to enable whole exome and RNA sequencing. AXL concentration was determined at T0 (pre-treatment) and T1 (after one cycle) time points using ELISA. Treatment response was dichotomized into those exhibiting any shrinkage or no change by RECIST1.1 – the R group (tumour reduction) and the NR group (any growth as the best outcome). We utilised geneset enrichment analysis and machine learning to identify relevant variables in the R vs. NR group.
Results
Histologically, 2 out of the 3 recruited patients with a non-epithelioid phenotype had a partial response or stable disease based on tumour size. Genomic features such as tumour mutation burden, somatic copy number burden, and aneuploidy were compared in R vs. NR, and no statistically significant difference was observed. However, specific copy number alterations involving NF2/22q loss were enriched in the R-group. GSEA revealed a markedly higher transcription related to EMT and pro-inflammatory response in the R-group. In contrast, oxidative phosphorylation and hypoxia were more enriched in the NR group.
Conclusions
This study suggests that EMT transcriptional activation facilitates the response to Bem/Pem in relapsed mesothelioma. Given the role of EMT in causing resistance to ICB, this combination could have a role following progression following standard first line therapy, and especially in patients with non-epithelioid mesotheliomas.
Legal entity responsible for the study
University of Leicester.
Funding
Asthma and Lung UK and Victor Dahdaleh Foundation Bergen Bio.
Disclosure
C. Poile: Other, Institutional, Funding, Research Funding: Boehringer Ingelheim. A. Thomas: Non-Financial Interests, Institutional, Advisory Board: BMS; Non-Financial Interests, Institutional, Speaker’s Bureau: Bristol Myers Squibb; Non-Financial Interests, Institutional, Expert Testimony: BMS. M.G. Krebs: Other, Institutional, Other, Honoraria: Roche; Other, Institutional, Advisory Board: Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen; Other, Institutional, Speaker’s Bureau: Janssen; Roche; Other, Institutional, Research Funding, Funding: Roche (Inst); Other, Institutional, Other, Travel, Accommodations, Expenses: AstraZeneca; BerGenBio; Immutep. D.A. Fennell: Other, Institutional, Other, Honoraria: Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Inventiva Pharma; Novocure; RS Oncology; Targovax; Other, Institutional, Advisory Role, Consulting or Advisory Role: Bristol Myers Squibb; Inventiva Pharma; Novocure; Roche; Targovax; Other, Institutional, Speaker’s Bureau: BMS; Boehringer Ingelheim; Other, Institutional, Research Funding: Astex Pharmaceuticals; Bayer; Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Fuji Pharma (Inst); lab21 (Inst); Other, Institutional, Other, Travel, Accommodations, Expenses: Bristol Myers Squibb; Janssen Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract